Frontlight ResearchEarly access
Taking people in HungaryPhase 4
Checks heart and blood vessel side effects of cancer immunotherapy drugs
Studies heart and blood vessel side effects in adults receiving immune checkpoint inhibitor cancer treatment.
Key facts
- Who runs it
- Semmelweis University
- Where
- Budapest VIII, HungarySee the site
- Trial code
- Registry title
- BudapestICIVasc: Cardiovascular side effects of immune checkpoint inhibitor oncological therapies and their monitoring in the context of onco-cardiology
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 1,000 people, planned
- Started
- 20 Jan 2026
- Expected to end
- 1 Jan 2031
- Type of study
- Interventional
- Record updated
- 14 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with cancer who are planning to start immune checkpoint inhibitor therapy. It studies the side effects on the heart and blood vessels.
- Age
- At least 18 years old.
- Sex
- All sexes can join.
- Earlier treatment
- Immune checkpoint inhibitor therapy must be planned.
Main reasons for not taking part
- No signed informed consent
- Under 18 years of age
- Cannot read or write (illiteracy)
- Pregnancy or breastfeeding
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Patients presented to the oncology teams of Semmelweis University and clinics in the country wishing to join the research
- Planned immune checkpoint inhibitor therapy
- At least 18 years of age
- Signing of the patient information sheet and consent form by the patient
- Accessible medical history
Who cannot take part
- Age under 18
- Lack of informed consent form
- Illiteracy
- Pregnancy and breastfeeding
Where in Hungary
- Semmelweis UniversityBudapest VIII, HungaryTaking people
About the trial
What the trial wants to find out
In this study, we aim to investigate the cardiovascular side effects of immune checkpoint inhibitors.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- BudapestICIVasc: Cardiovascular side effects of immune checkpoint inhibitor oncological therapies and their monitoring in the context of onco-cardiology
- Plain-language title
- Checks heart and blood vessel side effects of cancer immunotherapy drugsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 14 January 2026